Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mineralys Therapeutics, Inc.

14.25
+0.75005.56%
Post-market: 14.450.1999+1.40%19:56 EDT
Volume:1.30M
Turnover:18.26M
Market Cap:894.88M
PE:-3.89
High:14.40
Open:13.87
Low:13.53
Close:13.50
Loading ...

Company Profile

Company Name:
Mineralys Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2019
Employees:
51
Office Location:
150 N. Radnor Chester Rd.,Suite F200,Radnor,Pennsylvania,United States
Zip Code:
19087
Fax:
- -
Introduction:
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Directors

Name
Position
Brian Taylor Slingsby
Executive Chairman,Founder
Jon Congleton
Chief Executive Officer,Director
Alexander Asam
Director
Derek DiRocco
Director
Olivier Litzka
Director
Srinivas Akkaraju
Director
Takeshi Takahashi
Director

Shareholders

Name
Position
Jon Congleton
Chief Executive Officer,Director
Adam Levy
Chief Financial Officer, Chief Business Officer & Secretary
Brian Taylor Slingsby
Executive Chairman,Founder
David Rodman
Chief Medical Officer